SCHEMBL3985346

SCHEMBL3985346

Cc1nn(Cc2ccc(F)c(F)c2)c(=O)c2c(O)c3n(c12)CCN(C)C3=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.36
PKLR P30613 3/20 0.36
P2RY14 Q15391 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MAOB P27338 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
ADRA1B P35368 1/20 0.33
P2RX7 Q99572 2/20 0.33
HTT P42858 2/20 0.32
BRD4 O60885 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PTGER4 P35408 1/20 0.32
MAPK3 P27361 1/20 0.31
MAPK1 P28482 1/20 0.31
KCNH2 Q12809 1/20 0.31
CLPP Q16740 1/20 0.31
CACNA1H O95180 1/20 0.31
PTGS1 P23219 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3983532 0.89 PKM (0.44) PKMPKLRALDH1A1HTTKMT2A
SCHEMBL16253799 0.89 PKM (0.36) PKMPKLRP2RY14ALDH1A1MAOB
SCHEMBL3985002 0.88 NPBWR1 (0.35) PKMPKLRMEN1KMT2APOLB
SCHEMBL3986662 0.88 GAA (0.38) PKMPKLRALDH1A1HTTMEN1
SCHEMBL3983972 0.88 RXFP1 (0.40) PKMPKLRALDH1A1HTTPOLB
SCHEMBL3985863 0.87 PKM (0.35) PKMPKLRALDH1A1HTTMEN1
SCHEMBL3981492 0.86 MAOB (0.40) ALDH1A1MAOBHTTPOLB
SCHEMBL3989304 0.86 LMNA (0.41) PKMPKLRALDH1A1MAOBHTT
SCHEMBL3992564 0.85 PDE5A (0.38) ALDH1A1MAOBHTTMEN1KMT2A
SCHEMBL3985461 0.85 PDE5A (0.39) MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP PKM 1268/4885PKLR 519/4885P2RY14 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.